Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK2 V617F JAK2 Y931C |
Therapy | Ruxolitinib |
Indication/Tumor Type | cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F JAK2 Y931C | cancer | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331). | 21393331 |
PubMed Id | Reference Title | Details |
---|---|---|
(21393331) | Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. | Full reference... |